| Document |
Document Title |
|
WO/2018/103239A1 |
Disclosed is a preparation method for a compound shown by formula (E), a Velpatasvir intermediate shown by formula (K) and an analogue thereof. The method of the present invention uses inexpensive and easily available materials, and a si...
|
|
WO/2018/106518A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
|
WO/2018/099836A1 |
An object is to provide a planarizing coating-forming composition having high etching resistance and good gap filling property. Another object is to provide a method for manufacturing a device using the planarizing coating-forming compos...
|
|
WO/2018/099431A1 |
Disclosed is a pyrene organic compound having the following structural formula. The pyrene organic compound has better charge transfer performance and luminous efficiency, and also has better thermal stability. Therefore, by providing an...
|
|
WO/2018/101377A1 |
The present invention provides a compound having a specific structure represented by formula (0), a resin having a constituent unit derived from said compound, various compositions containing said compound and/or said resin, and various ...
|
|
WO/2018/099432A1 |
The present invention relates to a fused ring compound and a preparation method and application thereof. The fused ring compound is represented by general formula (I). The fused ring compound emits fluorescence at a short wavelength, and...
|
|
WO/2018/101207A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal composition that makes it possible to manufacture an optical film that has excellent light resistance; and an optically anisotropic membrane, an opt...
|
|
WO/2018/101463A1 |
The present invention is a compound having a specific structure, a resin having structural units derived from said compound, various compositions containing said compound and/or said resin, and various methods in which said compositions ...
|
|
WO/2018/101376A1 |
The present invention is a compound having a specific structure represented by formula (0), a resin having structural units derived from said compound, various compositions containing said compound and/or said resin, and various methods ...
|
|
WO/2018/099848A1 |
An object is to provide a planarizing coating-forming composition that exhibits high etching resistance, good gap filling property, and high flatness. Another object is to provide a method for manufacturing a device using the planarizing...
|
|
WO/2018/095132A1 |
An electroplating copper layer includes bamboo-like copper crystal particles having a highly preferred orientation. The bamboo-like copper crystal particles have a long axis direction and a short axis direction, and the bamboo-like coppe...
|
|
WO/2018/097215A1 |
The present invention is: a compound having a specific structure; a resin having a structural unit derived from the compound; various compositions containing the compound and/or the resin; and various methods in which the composition is ...
|
|
WO/2018/091756A1 |
The present invention relates to bioconjugates and derivatives of ochratoxin A labelled at different positions in the molecule suitable for the production of antibodies with a high affinity for ochratoxin A. Moreover, the present inventi...
|
|
WO/2018/092921A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions ...
|
|
WO/2018/087126A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful ...
|
|
WO/2018/089400A1 |
Methods of treatment of MIF-related diseases and methods of MIF inhibition are provided.
|
|
WO/2018/085787A1 |
A photocatalyst can be regenerated with increasing efficiency, turnover number and turnover frequency in the presence of air by irradiating the photocatalyst, preferably eosin Y, with a first range of wavelengths of light that excite the...
|
|
WO/2018/083713A1 |
The present invention discloses a novel, stable and synergistic combination of epicatechin with anti-cancer compounds. The present invention also discloses a composition comprising the novel combination of epicatechin with anti-cancer co...
|
|
WO/2018/080066A1 |
The present invention relates to a new compound and an organic electroluminescent device comprising the same. As the compound according to the present invention is used for an organic layer of an organic electroluminescent device, and pr...
|
|
WO/2018/073321A1 |
The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected ...
|
|
WO/2018/073828A1 |
Disclosed herein are compounds that are selective DNA primase and/or gyrase inhibitors. Further disclosed are pharmaceutical compositions comprising these compounds, and the uses of these compounds for treating disorders associated with ...
|
|
WO/2018/065807A1 |
The present invention relates to new chemical compounds of formula (I) with a structure different from nitroimidazoles, and to equally novel uses thereof for the treatment of trichomoniasis, making said compounds useful for application b...
|
|
WO/2018/065809A1 |
The present invention relates to pharmaceutical compositions that can be used for the treatment of trichomoniasis, which comprise compounds with the chemical structure and which also exhibit a synergic effect and do not have the typical ...
|
|
WO/2018/066872A1 |
The present invention relates to a 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative, a method for synthesizing an optical isomer thereof, and an intermediate compound usable in the synthesis method. The use of the method a...
|
|
WO/2018/058235A1 |
The present invention provides modified release pharmaceutical composition comprising one or more natural or synthetic cannabinoids and one or more pharmaceutically acceptable excipients. More specifically, the invention relates to modif...
|
|
WO/2018/056530A1 |
The present invention relates to an ibuprofen conjugate in which ibuprofen (S-(+)-ibuprofen) is covalently linked to a guanidine terminal group-coupled sugar alcohol derivative and a pharmaceutical composition comprising the same. The ib...
|
|
WO/2018/054507A1 |
The invention relates to photochromic multiple ring-fused naphthopyrans having closed-form extreme longwave absorption extending far into the visible wavelength range, as well as to the use thereof in plastics of all types, particularly ...
|
|
WO/2018/053643A1 |
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...
|
|
WO/2018/053240A1 |
Disclosed herein are compounds useful for modulating the mu-opioid receptor ("MOR") and/or delta-opioid receptor ("DOR"), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herei...
|
|
WO/2018/052026A1 |
The present invention provides a compound that is represented by formula (0). (In formula (0): RY is a hydrogen atom; RZ is a C1-60 N-valent group or a single bond; each RT is independently an optionally substituted C1-30 alkyl group, an...
|
|
WO/2018/052028A1 |
The present invention provides a compound that is represented by formula (0). (In formula (0), RY is a C1-30 alkyl group or a C6-30 aryl group; RZ is a C1-60 N-valent group or a single bond; each RT is independently an optionally substit...
|
|
WO/2018/045424A1 |
The invention relates to terpenes and uses thereof.
|
|
WO/2018/049263A1 |
The present disclosure provides methods and kits for treating or slowing the progression of a hematological malignancy, by administering to a subject in need thereof a therapeutically effective amount of: (i) at least one inhibitor of PI...
|
|
WO/2018/043567A1 |
The purpose of the present invention is to discover a cytotoxic anticancer drug that serves as a common substrate for both ABCB1 and ABCG2 which are suppressed in human pluripotent stem cells, and to provide a method for efficiently remo...
|
|
WO/2018/042291A1 |
The present invention relates generally to compositions and methods of use that include compounds and compositions that treat and/or prevent virus infections such as mosquito borne flaviviruses Zika and dengue and alphavirus chikungunya ...
|
|
WO/2018/042437A1 |
Color conversion films for a LCD (liquid crystal display) having RGB (red, green, blue) color filters, as well as such displays, formulations, precursors and methods are provided, which improve display performances with respect to color ...
|
|
WO/2018/045217A1 |
Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effectiv...
|
|
WO/2018/042409A1 |
This invention is directed to photoluminescent compounds based on rhodamine dyes with green emission and uses thereof for photoluminescence based devices.
|
|
WO/2018/039376A1 |
The present invention relates to monoterpenoid and phenylpropanoid containing derivative compounds, methods of making the compounds, compositions comprising the compounds, and methods of repelling pests using the compounds and/or composi...
|
|
WO/2018/039282A1 |
This invention is directed to methods for the facile and accurate identification of cancer cells in a tissue sample, such as a surgical field. In particular, the compositions and methods employ conjugates comprising pro-fluorescent fluor...
|
|
WO/2018/037279A1 |
The present invention is directed to a class of anti-inflammatory, antioxidant nitroalkene compounds used in biological or biochemical applications to reduce oxidative stress or damage. The nitroalkene compounds described herein further ...
|
|
WO/2018/033088A1 |
Provided are a five-membered ring substituted compound having xanthone as the core and applications thereof. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking molecular symm...
|
|
WO/2018/035296A1 |
Kinases can be engineered to utilize an ATP analog that is not readily utilized by wild-type kinases by introducing a mutation in the ATP-binding pocket. However, application of this method has been limited by the membrane impermeability...
|
|
WO/2018/031853A1 |
Disclosed is an optical compensation film made of a solution cast of a polymer blend comprising a nitrated styrenic fluoropolymer and a polyimide. The compensation film is a positive-C plate having reversed wavelength dispersion that is ...
|
|
WO/2018/030550A1 |
The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.
|
|
WO/2018/030786A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising the same.
|
|
WO/2018/026538A1 |
Disclosed are folic acid or pteroic aicd conjugates and methods for using such conjugates. The conjugates described herein comprise a chemotherapeutic drug or imaging agent covalently bound thereto through a bond or via a linker that is ...
|
|
WO/2018/020974A1 |
Provided are the following: a sulfonium salt which does not contain a toxic metal and which exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt; a heat- or photo-...
|
|
WO/2018/022868A1 |
The present invention provides a plant-based flavonoid pharmaceutical composition and its synthetic for inhibition of phosphau'dylinositol-4-kinases and consequent prevention and treatment of RNA viruses including but not limited to vira...
|
|
WO/2018/023072A2 |
Disclosed are compounds of formula (I), and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
|
